Akebia Therapeutics (AKBA) Operating Income Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Operating Income Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 25.63% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -1.30% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | -319.32% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -14.89% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | 97.23% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 719.49% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 21.25% |
| 10 | Akebia Therapeutics | 341.82 Mn | 179.22 Mn | 41.25 Mn | -134.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134.75% |
| Dec 31, 2025 | 40.22% |
| Sep 30, 2025 | 135.58% |
| Jun 30, 2025 | 261.48% |
| Mar 31, 2025 | 190.48% |
| Dec 31, 2024 | -1,141.27% |
| Sep 30, 2024 | 4.07% |
| Jun 30, 2024 | 3.01% |
| Mar 31, 2024 | 41.65% |
| Dec 31, 2023 | 128.22% |
| Sep 30, 2023 | 74.14% |
| Jun 30, 2023 | -126.40% |
| Mar 31, 2023 | 57.04% |
| Dec 31, 2022 | 92.55% |
| Sep 30, 2022 | 8.16% |
| Jun 30, 2022 | 142.95% |
| Mar 31, 2022 | 8.25% |
| Dec 31, 2021 | 23.49% |
| Sep 30, 2021 | 5.52% |
| Jun 30, 2021 | 54.35% |